In-person registrations are now closed as the event has reached the threshold for onsite participation. We thank you for your interest and apologize for any inconvenience.
Where: József Antall (JAN), room 6Q1
When: Tuesday 29 November 2022, 15:00 -17:00
|15:00 - 15:10||Welcome address
Dr Stelios Kympouropoulos, MEP
|15:10 – 15:25||The State of the ATMP sector in Europe
Tim Hunt, Chief Executive Officer, Alliance for Regenerative Medicine
|15:25 – 15:40||Testimonial from the first pediatric patient cured with CAR-T therapy
Emily Whitehead & Tom Whitehead, Emily Whitehead Foundation
|15:40 – 15:55||EU initiatives of relevance to the ATMP sector
Sylvain Giraud, Head of Unit ‘Medical Products: Quality, Safety, Innovation’, DG Sante, European Commission
|15:55 – 16:55||Panel discussion: How to improve patient access to ATMPs in Europe?
Patrick Celis, Scientific Administrator, Committee for Advanced Therapies, European Medicines Agency
Lucy Ellerker, Patient Advocate
Simone Boselli, Director of Public Affairs, EURORDIS Rare Disease Europe
Susana Solís Perez, MEP
Chris Vann, Chief Operating Officer at Autolus, and Member of the Alliance for Regenerative Medicine’s Board
|16:55 – 17:00||Concluding remarks
Dr Miguel Forte, President-Elect of the International Society for Cell & Gene Therapy, and Member of the Alliance for Regenerative Medicine’s Board
The Alliance for Regenerative Medicine is committed to data privacy and protecting your personal information. By submitting your email address during the conference registration process, you agree that the Alliance for Regenerative Medicine may send you conference-related information. A valid email address is required for all registrations. The Alliance for Regenerative Medicine may disclose your personal data to third-party service providers engaged to assist in the planning of the conference. The information you provide when registering may be shared with those parties, and the treatment of such information is further subject to the privacy policies of those parties.